Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Genzyme's Cerezyme

Executive Summary

Genzyme's Cerezyme: Allston Landing plant in Boston approved by FDA for manufacture of the recombinant glucocerebrosidase product. Genzyme will begin to ship drug supplies from the plant by year end. Cerezyme has been available in very limited supply since its approval in 1994, with 90% of the 1,700 Gaucher's disease patients being treated with enzyme replacement still receiving the nonrecombinant glucocerebrosidase Ceredase...



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts